Under settlement, FDA has to pre-approve Merck ads

One feature of Merck and Schering-Plough's settlement with 35 state attorneys general is a provision requiring the companies to get FDA to bless all its DTC advertisements--not just those for Vytorin, the cholesterol med that prompted the probe--before airing or publishing them. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.